Today not only marks World AIDS Day, but also marks the 30th anniversary of when the AIDS virus was officially recognized continue reading...
ScienceDaily (Apr. 29, 2008) — A research group supported by the National Institutes of Health (NIH) has uncovered a new route for attacking the human immunodeficiency virus (HIV) that may offer a way to circumvent problems with drug resistance. In findings published April 28 in the online edition of the Proceedings of the National Academy of Sciences, the researchers report that they have blocked HIV infection in the test tube by inactivating a human protein expressed in key immune cells. Read more continue reading...
TORONTO, ONTARIO–(Marketwire - March 27, 2008) -
continue reading...
OAKLAND, Calif., Dec. 20 /PRNewswire/ — The largest study to examine the effect of depression on HIV treatment found that depression significantly worsens a patient’s adherence to highly active antiretroviral therapy and clinical measures, but that effective antidepressant medication can reverse this outcome, according to a study by the Kaiser Permanente Division of Research and the Group Health Cooperative published in the current online issue of the Journal of Acquired Immune Deficiency Syndromes (JAIDS).
The study looked at 3,359 HIV-infected patients from seven Kaiser Permanente regions nationwide and Group Health in 2000 to 2003 to measure the effects of depression — with and without selective serotonin reuptake inhibitors (SSRI) use — on adherence and changes in viral and immunologic control in patients starting a new highly active antiretroviral therapy (HAART) regimen. continue reading...
TORONTO, Sept. 21 /PRNewswire/ - The Federal Commissioner of Patents issued today a compulsory licence for ApoTriavir under Canada’s Access to Medicines Regime Program (CAMR) allowing Apotex to proceed with manufacturing of the product. This drug, a triple combination AIDS therapy, was the first product to be approved by Health Canada under the provisions of the CAMR. ApoTriavir was approved by Health Canada in August 2006 and is pre-qualified by the World Health Organization.
The CAMR was designed to help developing countries that have little or no pharmaceutical manufacturing capacity in their fight against HIV/AIDS, tuberculosis, malaria and other diseases. continue reading...
A drug used to treat people infected with the AIDS virus has shown promise as a possible future weapon against cancer, U.S. researchers said on Friday.
Scientists at the U.S. National Cancer Institute examined how drugs called protease inhibitors, usually given in combination with other drugs to fight the human immunodeficiency virus, or HIV, performed against several types of cancer including non-small cell lung cancer. continue reading...
